ライフサイエンスコーパス: fallopian tube

1 ainly located in the upper tract (uterus and fallopian tubes).

2 are ectopic, the majority implanting in the Fallopian tube.

3 the ovary, namely the secretory cells of the fallopian tube.

4 ectopic pregnancy is embryo retention in the fallopian tube.

5 g the testes, epididymis, uterus, ovary, and fallopian tube.

6 t was also present on time epithelium of the fallopian tube.

7 receptor (FSHR) expression in the ovary and fallopian tube.

8 ube hypothesis, we found most lesions in the fallopian tube.

9 al dissemination of precursor lesions of the fallopian tube.

10 ht to originate in the distal portion of the fallopian tube.

11 s such as the respiratory epithelium and the fallopian tube.

12 lls but not from the proximal portion of the fallopian tube.

13 and in the general population arise from the fallopian tube.

14 death and sloughing of ciliated cells of the Fallopian tube.

15 the lower genital tract into the uterus and fallopian tubes.

16 epithelia in brain ventricles, airways, and Fallopian tubes.

17 proximal and distal TE regions of 12 normal Fallopian tubes.

18 production and ciliated cell death in human fallopian tubes.

19 be caused by pelvic adhesions affecting the fallopian tubes.

20 tasis in an ex vivo infection model of human fallopian tubes.

21 e revealing the influence of estrogen on the fallopian tubes.

22 0 and are also predisposed to cancers of the fallopian tubes.

23 mullerian duct-derived epithelium of normal fallopian tubes.

24 salpingography to depict normal and diseased fallopian tubes.

25 s in the toxicity of N. gonorrhoeae to human fallopian tubes.

26 tudy patients with surgically proved dilated fallopian tubes.

27 proteome of lavages from disease vs. healthy fallopian tubes.

28 ncer, originating from the epithelium of the fallopian tubes.

29 ouse oviduct and was also expressed in human fallopian tubes.

30 od, lymph nodes, vagina, cervix, uterus, and fallopian tubes.

31 essed by normal endocervix, endometrium, and fallopian tube (60, 64, and 29% of specimens, respective

32 mon biologic origin, likely to be the distal fallopian tube among all cases.High-grade serous carcino

33 nce of blood in a dilated retort-shaped left fallopian tube and a normal right uterus.

34 to 40 years of age, had at least one patent fallopian tube and a normal uterine cavity, and had a ma

35 ealed highest expression of this molecule in fallopian tube and cervical tissues, followed by endomet

36 ol for fast assessment of ovarian tissue and fallopian tube and could avoid unnecessary surgery if th

37 raepithelial carcinoma in the fimbria of the fallopian tube and involves the ovary secondarily.

38 Cytology identifies 91 endometrial, two fallopian tube and one cervical cancer from 103 known ca

39 rovide a novel therapeutic strategy to treat fallopian tube and ovarian HGSC.

40 al role in the initiation and progression of fallopian tube and ovarian HGSC.

41 f open chromatin and histone modification in fallopian tube and ovarian surface epithelial cells (FTS

42 lt malignancies were discovered, four in the fallopian tube and three in the ovaries.

43 velop from intraepithelial carcinomas in the fallopian tube and, as a result, disseminate as carcinom

44 sets to gene expression sets of eight normal fallopian tubes and 499 high-grade serous malignant ovar

45 MR imaging can depict most dilated fallopian tubes and differentiate them from other adnexa

46 ith highest expression in the upper tissues (fallopian tubes and endometrium), followed by cervix and

47 water produced good images of the simulated fallopian tubes and free spill.

48 By contrast, the upper FRT (uterus, Fallopian tubes and ovaries) might be sterile in healthy

49 is commonly result in ascending infection to fallopian tubes and subsequent immune-mediated tubal pat

50 ing genital infections cause inflammation of fallopian tubes and subsequent scarring and occlusion.

51 ere, we developed organoids from human fetal fallopian tubes and uteri and compared them with their a

52 hazard ratios (HRs) and 95% CIs for ovarian, fallopian tube, and peritoneal cancer combined.

53 nd BRCA2 increase risks for breast, ovarian, fallopian tube, and peritoneal cancer in women; interven

54 ted with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer.

55 are relatively common in women with ovarian, fallopian tube, and peritoneal carcinoma (OC) causing a

56 women are for cancers of the breast, ovary, fallopian tube, and peritoneum.

57 st and BRCA-associated gynecologic (ovarian, fallopian tube, and primary peritoneal) cancer.

58 A phantom simulating the uterus, fallopian tubes, and surrounding pelvic cavity was const

59 denocarcinomas originating from the ovaries, fallopian tubes, and the peritoneum.

60 Intraepithelial carcinomas of the fallopian tube are putative precursors to high-grade ser

61 In this review, evidence supporting the fallopian tube as the origin of ovarian cancer is presen

62 taining the relevant cell types of the human fallopian tube as well as a luminal architecture that cl

63 op high-grade serous cancers, removal of the fallopian tube at an early age prevents cancer formation

64 To address the need for a fallopian tube-based model of HGSOC, we have developed a

65 serous peritoneal carcinoma arising from the fallopian tube before it spreads.

66 Adhesion molecules were identified in fallopian tube biopsy specimens cultured with 5 x 10(6)

67 and BRCA2 carriers after RRBSO with ovarian, fallopian tube, breast, and peritoneal cancer published

68 factors for PID, confirmed PID, and occluded fallopian tubes but not with acute C. trachomatis infect

69 by normal vagina and ectocervix and inflamed fallopian tube, but variably expressed by normal endocer

70 Chlamydia trachomatis infection of the human fallopian tubes can lead to damaging inflammation and sc

71 Hydrosalpinx, the blockage of fallopian tubes, can result from pelvic inflammatory dis

72 women at high risk of ovarian cancer (OC) or fallopian tube cancer (FTC).

73 ge III or IV ovarian, primary peritoneal, or fallopian tube cancer (newly diagnosed, cohort one; rela

74 ve recurrent ovarian, primary peritoneal, or fallopian tube cancer (ROC).

75 cinoma of the peritoneum (four patients), or fallopian tube cancer (two patients) who previously had

76 V epithelial ovarian, primary peritoneal, or fallopian tube cancer and were not selected for EGFR exp

77 ients with recurrent ovarian, peritoneal, or fallopian tube cancer have limited therapeutic options.

78 current OC, primary peritoneal carcinoma, or fallopian tube cancer in comparison with physician's cho

79 varian cancer, primary peritoneal cancer, or fallopian tube cancer with a BRCA mutation; and were in

80 id Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer), which tested rucaparib as HGOC t

81 ncer and 228 had died; 57 died of ovarian or fallopian tube cancer, 58 died of breast cancer, 16 died

82 e epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response

83 rian cancer, including primary peritoneal or fallopian tube cancer, and had received two or more prev

84 tage IIIC/IV ovarian, primary peritoneal, or fallopian tube cancer.

85 ients with recurrent ovarian, peritoneal, or fallopian tube cancer.

86 recurrent EOC, peritoneal serous cancer, or fallopian tube cancer.

87 ioid cancer, including primary peritoneal or fallopian tube cancer.

88 Two patients with ovarian/fallopian tube cancers had partial remissions for 5.2 an

89 l resemblance to human serous cancers, these fallopian tube cancers highly express genes that are kno

90 It has been proposed that fallopian tube cancers may be precursors of HGSOC but ev

91 II trial included the following: ovarian and fallopian tube cancers or primary carcinoma of the perit

92 -one breast, ovarian, primary peritoneal, or fallopian tube cancers were detected after receipt of ge

93 V epithelial ovarian, primary peritoneal, or fallopian tube cancers, and an ECOG performance status o

94 0 (16%) had peritoneal cancer, four (6%) had fallopian tube cancers, and three (5%) had uterine papil

95 and recurrent somatic mutations in sporadic fallopian tube cancers.

96 ian cancer, including primary peritoneal and fallopian tube cancers.

97 Fallopian tube carcinoma (FTC) is a rare, poorly studied

98 tations among Ashkenazi Jewish patients with fallopian tube carcinoma (FTC) or primary peritoneal car

99 endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma and an Eastern Cooperative Onco

100 V epithelial ovarian, primary peritoneal, or fallopian tube carcinoma and an Eastern Cooperative Onco

101 s isolated from a previous transgenic murine fallopian tube carcinoma model, and confirmed that loss

102 t epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with a maximum of two prior che

103 d epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with first disease recurrence m

104 endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two prev

105 d for all women with ovarian, peritoneal, or fallopian tube carcinoma, regardless of age or family hi

106 m women with primary ovarian, peritoneal, or fallopian tube carcinoma.

107 ed from UW, there was a higher proportion of fallopian tube carcinomas (13.3% vs 5.7%; P < .001); sta

108 the level of genomic aberration observed in fallopian tube carcinomas compared with high-grade serou

109 a genome-wide copy number analysis of occult fallopian tube carcinomas identified through risk-reduci

110 ubal intraepithelial carcinomas (STICs), and fallopian tube carcinomas), ovarian cancers, and metasta

111 ade that primary ovarian epithelial tumours, fallopian tube carcinomas, and primary peritoneal carcin

112 Fallopian tube cells displayed a p53-independent increas

113 ertussis and has been shown to kill ciliated fallopian tube cells in organ culture.

114 fining factor in transcriptional response of fallopian tube cells to long-term NE treatment.

115 Fallopian tube cells with mutant p53 showed a mild loss

116 tudies examining the transformation of human fallopian tube cells.

117 for temporal resolution, spatial resolution, fallopian tube conspicuity, and free spill conspicuity.

118 The precancerous landscape in fallopian tubes contains multiple concurrent precursor l

119 However, the molecular pathogenesis of fallopian tube-derived serous carcinomas is poorly under

120 biology, as well as for developing models of fallopian tube disease, such as cancer.

121 e compared with surgical findings of dilated fallopian tube, endometriosis, and salpingitis.

122 s end, the adhesion molecules induced on the fallopian tube endothelium during infection with C. trac

123 and is also expressed in ovarian surface and fallopian tube epithelia.

124 g were investigated by using cultured bovine fallopian tube epithelial (BFTE) cells inoculated with C

125 ctive oocyst) in a primary culture of bovine fallopian tube epithelial (BFTE) cells.

126 s ~3-15-fold more potently than immortalized fallopian tube epithelial (paired normal control) cells

127 SEC) cultures are useful for studying normal fallopian tube epithelial biology, as well as for develo

128 This human fallopian tube epithelial cell culture model is an impor

129 We developed a primary human fallopian tube epithelial cell model based on a method p

130 ntify novel and specific biomarkers of early fallopian tube epithelial cell transformation.

131 tions and LPA signaling, we utilized primary fallopian tube epithelial cells (FTEC) engineered to ove

132 talized ovarian surface epithelial cells and fallopian tube epithelial cells via a single-run mass sp

133 In the current study, primary human fallopian tube epithelial cells were infected with N. go

134 gestion and physical dissociation of excised fallopian tubes, epithelial cell precursors were expande

135 arcinoma (HGSOC) remains controversial, with fallopian tube epithelium (FTE) and ovarian surface epit

136 ogenic drivers and origination from both the fallopian tube epithelium (FTE) and ovarian surface epit

137 Recent insights supporting the fallopian tube epithelium (FTE) and serous tubal intraep

138 ed by the molecular signatures of the normal fallopian tube epithelium (FTE) cells, the cells of orig

139 The fallopian tube epithelium (FTE) has been recognized as a

140 The fallopian tube epithelium (FTE) is one of the progenitor

141 an surface epithelium (n = 31; P = 0.039) or fallopian tube epithelium (n = 28; P < 0.001).

142 op new and robust model systems to study the fallopian tube epithelium as the cell of origin of "ovar

143 experimental model systems for studying the fallopian tube epithelium in high-risk women as well as

144 ad molecular profiles more similar to normal fallopian tube epithelium than ovarian surface epitheliu

145 Although highly expressed in normal fallopian tube epithelium, ACP6 expression was significa

146 Ovarian surface epithelium and fallopian tube epithelium, not previously recognized to

147 inomas involving the ovary likely arise from fallopian tube epithelium.

148 ls, recapitulating the architecture of human fallopian tube epithelium.

149 iosis on the ciliary beat frequency of human fallopian tube epithelium.

150 isseria gonorrhoeae trafficking across human fallopian tube epithelium.

151 ity compared with adjacent, normal-appearing fallopian tube epithelium.

152 e STICs, carcinoma, and their matched normal fallopian tube epithelium.

153 rimarily imported from either endometrial or fallopian tube epithelium.

154 erleukin-8 (IL-8) secretion in primary human fallopian tube explants.

155 difference in ciliary beat frequency between fallopian tubes exposed to peritoneal fluids of women wi

156 ions of genital chlamydial infection include fallopian tube fibrosis and tubal factor infertility.

157 his article, we discuss the emergence of the fallopian tube fimbria as a field of origin for high-gra

158 %) of 147 women with PID and from ovaries or fallopian tubes from 5 (22.7%) of 22 women with PID, but

159 Fallopian tubes from hysterectomy specimens were collect

160 ous ovarian carcinomas (SOCs) arise from the fallopian tube (FT) epithelium rather than the ovarian s

161 Fallopian tube (FT) from women with EP exhibit altered e

162 Fallopian tube (FT) homeostasis requires dynamic regulat

163 In EP, embryo retention within the Fallopian tube (FT) is thought to be due to impaired smo

164 Investigating the human fallopian tube (FT) microbiota has significant implicati

165 alysis of the mechanical properties of human fallopian tubes (FT) and ovaries revealed that normal FT

166 15 fallopian tubes (FT) from 14 women in reproductive age f

167 om multiple extra-ovarian origins, including fallopian tube, gastrointestinal tract, cervix and endom

168 26 patients with nonuniform sampling of the fallopian tubes (group 1) and 19 patients with complete

169 Brain, placenta and fallopian tube had the highest PI-TP RNA expression.

170 The fallopian tube has been proposed instead as the primary

171 mors of the ovary and Walthard cell nests of Fallopian tubes have been considered to represent urothe

172 Consistent with the fallopian tube hypothesis, we found most lesions in the

173 ays capturing physiological functions of the fallopian tube (i.e., oocyte transport), and whole-organ

174 In premenopausal fallopian tubes, IGFBP2 expression was limited to the se

175 primary samples of normal, nondiseased human fallopian tubes, (ii) transformation of FTSECs with defi

176 ome of the fimbrial and proximal ends of the fallopian tube in BRCA1/2 mutation carriers and non-carr

177 high-grade serous carcinomas arise from the fallopian tube in mice.

178 blinded readers correctly identified dilated fallopian tubes in 31 of 41 study patients and correctly

179 ells, and on cells that line the trachea and fallopian tubes in mammals.

180 s in accordance with known cyclic changes of fallopian tubes in response to ovarian hormones and may

181 vagina, ectocervix, endocervix, uterus, and fallopian tubes in the female reproductive tract.

182 invasive epithelial cancers of the ovary or fallopian tube (index cancers).

183 rly identical findings were found in macaque fallopian tubes infected in situ repeatedly with C. trac

184 The vascular pattern of benign fallopian tube is different than that of benign ovarian

185 The fallopian tube is now generally considered the dominant

186 ated by salpingectomy, in which the affected Fallopian tube is removed, or salpingotomy, in which the

187 for finding an extraovarian mass, since the fallopian tube is the most common location for ectopic p

188 ical evidence supports the position that the fallopian tube is the site of origin for a large proport

189 ber analyses of laser capture microdissected fallopian tube lesions (p53 signatures, serous tubal int

190 e show that PRKCI is also expressed in early fallopian tube lesions, called serous tubal intraepithel

191 Epithelial shedding and scarring of fallopian tube mucosa are the main consequences of sexua

192 y-stage ovarian neoplasm and one early-stage fallopian tube neoplasm were found.

193 Main outcome measures were nonovarian, non-fallopian tube, nonbreast, positive intra-abdominal peri

194 Patency of fallopian tubes not visualized at hysterosalpingography

195 atory response leads to chronic scarring and Fallopian tube obstruction.

196 hlamydial upper genital tract infection, the fallopian tubes of 40 female Macaca nemestrina were inoc

197 ual cycle, and were best coregistered to the fallopian tubes on contrast-enhanced CT.

198 s a possible origin of HGSOC either from the fallopian tube or from the ovarian surface epithelium.

199 st and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritoneal) cancer when BRCA2

200 ute complications may include rupture of the fallopian tube or rupture of ectopic pregnancy, haemorrh

201 ed each adnexa for the presence of a dilated fallopian tube or thickened tubal wall and mucosal folds

202 n hydrocephalus, defects in the cilia in the fallopian tubes or in sperm flagella can cause female an

203 older with stage III-IV epithelial ovarian, fallopian tube, or peritoneal cancer (following debulkin

204 d 18 years or older with epithelial ovarian, fallopian tube, or peritoneal cancer (maximum of three p

205 rapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinic

206 ith an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 c

207 o estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRC

208 observed until either diagnosis of ovarian, fallopian tube, or peritoneal cancer, death, or date of

209 ld have confirmation of an invasive ovarian, fallopian tube, or peritoneal cancer.

210 logy and Obstetrics stage IIB to IV ovarian, fallopian tube, or peritoneal epithelial carcinoma.

211 ly confirmed epithelial cancer of the ovary, fallopian tube, or peritoneum (any stage, grade 2 to 3 i

212 on after a diagnosis of cancer of the ovary, fallopian tube, or peritoneum (N = 404).

213 irmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of any hist

214 irmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of high-gra

215 with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IM

216 Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer were random

217 atients with suboptimal stage III or IV EOC, fallopian tube, or primary peritoneal cancer were random

218 resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer were random

219 de serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had bee

220 ve, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer) and the mu

221 , high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer, or those w

222 ry or -resistant epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

223 zumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma.

224 stage IIB-IV epithelial cancer of the ovary, fallopian tube, or primary peritoneum.

225 ential sites: the surfaces of the ovary, the fallopian tube, or the mesothelium-lined peritoneal cavi

226 increase in toxicity of the strain to human fallopian tube organ cultures (HFTOC).

227 In the human fallopian tube organ-culture model, Opa-producing varian

228 ge prevents cancer formation--confirming the fallopian tube origin of the cancer.

229 matory disease (PID) and surgical specimens (fallopian tubes, ovaries, or both) from 22 women with PI

230 ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may inc

231 e the endometrial and uterine morphology and fallopian tube patency.

232 populations: Primary (cells in the ovary or fallopian tube), Peritoneal (viable cells in peritoneal

233 al and serial sectioning of both ovaries and fallopian tubes, peritoneal and omental biopsies, and co

234 Because the fallopian tubes play a key role in ovarian cancer pathog

235 HGSCs frequently arise in the distal fallopian tubes rather than the ovary, developing from s

236 uring hysterosalpingography (0.04-0.55 cGy), fallopian tube recanalization (0.2-2.75 cGy), computed t

237 Five patients underwent simultaneous fallopian tube recanalization.

238 Secretions by epithelial cells of the fallopian tube regulate ovulation through conserved path

239 likely originate in the distal region of the Fallopian tube's epithelium (TE) before metastasizing to

240 HGSOC sample pairs from 11 patients, and in fallopian tube samples from five healthy women.

241 of eight (25%) animals tested positive from fallopian tube samples.

242 emale genital tract can lead to irreversible fallopian tube scarring.

243 female infertility due to infection-induced Fallopian tube scarring.

244 on acts to drive malignant transformation in fallopian tube secretory cells that are the site of orig

245 Primary human fallopian tube secretory epithelial cell (FTSEC) culture

246 e have developed a system for studying human fallopian tube secretory epithelial cell (FTSEC) transfo

247 With the rise of the fallopian tube secretory epithelial cell as a cell of or

248 al cells-ovarian surface epithelia cells and fallopian tube secretory epithelial cells (FTSEC).

249 The recent identification of the fallopian tube secretory epithelial cells (FTSECs) as th

250 rade serous carcinoma (HGSC) originates from fallopian tube secretory epithelial cells (FTSECs).

251 h factors for GAB2-induced transformation of fallopian tube secretory epithelial cells and clonogenic

252 we report that miR-181a is able to transform fallopian tube secretory epithelial cells through the in

253 In primary human fallopian tube secretory epithelial cells, cyclin E1 exp

254 potently transforms immortalized ovarian and fallopian tube secretory epithelial cells.

255 erous ovarian carcinoma commonly arises from fallopian tube secretory epithelium and is characterized

256 pecific binding for CTCF in HGSOC and normal fallopian tube secretory epithelium cells (FTSECs).

257 The distal fallopian tube seems to be the dominant site of origin f

258 ylation levels between fimbrial and proximal fallopian tube segments are threefold higher in BRCA mut

259 erous carcinoma, which often arises from the fallopian tubes, showed a weaker genetic correlation wit

260 s demonstrated using excised human ovary and fallopian tube specimens imaged immediately after surger

261 In positive endocervix, endometrium, and fallopian tube specimens, HD-5 was located in apically o

262 onstrated it on a limited set of ovarian and fallopian tube specimens.

263 is and identified bacterial 16S sequences in Fallopian-tube specimens from 11 (24%) of 45 consecutive

264 In the oviduct (fallopian tube), sperm undergo a process called "hyperac

265 n cancer, defined as limited to the ovary or fallopian tube (stage I) or confined to the pelvis (stag

266 omas are first observed in the stroma of the fallopian tube, suggesting that these epithelial cancers

267 ic aberrations that transform ovarian and/or fallopian tube surface epithelial cells, allowing for th

268 3D multicompartment assembloid model of the fallopian tube that molecularly, functionally, and archi

269 thal gynecologic malignancy arising from the fallopian tubes that has a high rate of chemoresistant r

270 er up in the female genital tract and in the fallopian tubes (the site of origin of high-grade serous

271 utively expressed in epithelial cells of the fallopian tube, the cell of origin of high-grade serous

272 an origin arise in the fimbriated end of the fallopian tube, this site cannot account for all of thes

273 ovarian cancer, posits to its development in fallopian tubes through stepwise tumor progression.

274 ockets generated by transplanting autologous Fallopian tube tissue subcutaneously.

275 describes the isolation of FTSECs from human fallopian tube tissue, conditions for primary FTSEC cult

276 tion in inflammation was most obvious in the fallopian tube tissue.

277 ifaceted platform with direct comparisons to fallopian tube tissue.

278 quantify the microvasculature of ovarian and fallopian tube tissue.

279 gly1 null mutant causes much more damage to fallopian tube tissues than its isogenic wild-type paren

280 Comparing HGSOC tumors with normal fallopian tube tissues we observe global hypomethylation

281 overexpressed in inflammatory and cancerous fallopian tube tissues.

282 ese Dicer-Pten double-knockout mice, primary fallopian tube tumors spread to engulf the ovary and the

283 ale breast (six cases), ovary (three cases), fallopian tube (two cases), pancreas (three cases), blad

284 SC recapitulating the likely cell of origin (fallopian tube), underlying genetic defects, histology,

285 + T cells both longitudinally within the RT (Fallopian tube, uterine endometrium, endocervix, ectocer

286 NA expression of TLRs 1 to 6 was observed in fallopian tubes, uterine endometrium, cervix, and ectoce

287 male reproductive tissues, prostate, testis, fallopian tube, uterus, and placenta, as well as in pros

288 e loops between organ modules for the ovary, fallopian tube, uterus, cervix and liver, with a sustain

289 ns and isolated cell cultures from the human fallopian tube, uterus, cervix, and vaginal mucosa were

290 recombinase in tissues that develop into the fallopian tubes, uterus, and ovaries.

291 ogical cancers may originate in the ovary or fallopian tubes, uterus, cervix, and the vagina or vulva

292 0.139), site of tumor origin (ovaries versus fallopian tubes versus peritoneum) (P = 0.170), and prim

293 The FSHR expression in the ovary and fallopian tube was confirmed by reverse transcription po

294 The signal intensity of normal fallopian tubes was intermediate on T2-weighted images a

295 Between normal ovaries and normal fallopian tubes, we observed significant differences in

296 to 40 years of age with at least one patent fallopian tube were randomly assigned to ovarian stimula

297 anatomy of the ovary, functional cysts, and fallopian tubes were correlated with findings at histopa

298 ous ovarian cancer (HGSOC) originates in the fallopian tube, where the earliest known genetic lesion

299 In postmenopausal fallopian tubes, where most STICs are detected, IGFBP2 i

300 e from secretory epithelial cells within the Fallopian tube, which first develops as serous tubal int